Organon | Sustainability Performance
Develops and manufactures pharmaceutical products, focusing on women's health, biosimilars, and established medicines across various therapeutic areas.
1923
United States
5,001 - 10,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#636
Overallⓘ#161
in United Statesⓘ#19
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsCarbon certificatesEnergy consumptionWaste ManagementWater ManagementSocial
Diversity and InclusionGovernance
TargetsFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Critical
Aligned
Leading
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
7.1
B/M 13.9
150.0
B/M 111.2
31.7
B/M 65.5
1.0
B/M 1.1
Powered by illuminem and GIST Impact
Controversy level
- Organon's spin-off from Merck carried significant debt and revenue concentration risks.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
11+
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.